

Policy Statement – Prescribing of Bazedoxifene plus conjugated oestrogens (Duavive®) for post-menopausal symptoms in women with a uterus is not supported.

Mid Essex Clinical Commissioning Group (MECCG) does not support the prescribing of Bazedoxifene plus conjugated oestrogens (Duavive®) for the treatment of post-menopausal symptoms in women with a uterus.

Bazedoxifene acetate is a third generation selective oestrogen receptor modulator (SERM), similar to raloxifene, and has oestrogen-receptor agonist effects on bone, and antagonist effects on uterine and breast tissue. When a SERM is paired with an oestrogen, it forms a tissue-selective estrogen complex (TSEC); a novel class of therapeutic agents, which achieve an optimal blend of estrogen receptor agonist and antagonist effects for the treatment of menopausal symptoms and prevention of osteoporosis.

The East of England Priorities Advisory Committee have advised that routine commissioning of bazedoxifene plus conjugated oestrogens (Duavive®) for the treatment of post-menopausal symptoms in women with a uterus is currently **NOT** recommended because:

- There is insufficient evidence to quantify the risks and benefits compared to current alternative treatments
- There are no long term safety data.
- Information on cost effectiveness and cost impact is not currently available.

The full evidence review can be found here <https://www.prescqipp.info/resources/category/328-bazedoxifene-plus-conjugated-oestrogens>

Providers commissioned to provide services on behalf of Mid-Essex CCG are reminded that they are required to follow the Mid-Essex CCG formulary and prescribing guidance as detailed in their contract (Medicines Management Service Specification).

See Mid-Essex CCG website – Medicines optimisation for all prescribing guidance.

<http://midessexccg.nhs.uk/your-health-services/medicines-optimisation>

Title	Bazedoxifene plus conjugated oestrogens (Duavive®) policy statement
Document reference	BazedoxifeneplusConjugatedOestrogensPOL201610V1.0FINAL
Author	Medicines Optimisation Team, Mid-Essex CCG
Reference:	East of England Priorities Advisory Committee - Full evidence review for Bazedoxifene plus conjugated oestrogens. https://www.prescqipp.info/resources/category/328-bazedoxifene-plus-conjugated-oestrogens Last accessed 10 Oct 2016
Approved by	Mid Essex Area Prescribing Committee
Date approved	January 2017
Next review date	January 2019

Previous version	Key Changes
New document	N/A